Company profilePharmaceutical#267 of 1,318 in Pakistan✓ No DRAP alerts

PARKE DAVIS & COMPANY LTD.

Pharmaceutical company · 69 brands · 108 molecules

Ranked #189 of 311 companies in Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord)

69 registered products 29 pharmaceutical brands 108 distinct molecules 0 DRAP alerts

Company overview

69
registered products
29
pharmaceutical brands
108
distinct molecules
9
therapeutic classes
0
DRAP alerts

PARKE DAVIS & COMPANY LTD. is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 69 product registrations across 108 distinct molecules. Its portfolio is concentrated in Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord) and Macrolides, Lincosamides And Streptogramins. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Top molecules by brand count

Paracetamol4 brands
Piroxicam3 brands
Diclofenac3 brands
Sodium3 brands
Cefepime2 brands
Mepyramine2 brands
Caffeine2 brands
Nicotinamide2 brands

Therapeutic classes

Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord) · 2Macrolides, Lincosamides And Streptogramins · 1Antianemic, Iron Preparations · 1Blood Glucose Lowering Drugs, Excluding Insulin · 1Other Beta-Lactam, Cephalosporins & Penems · 1Antimycotics Systemic Use · 1Antiemetics & Antinauseants · 1Drugs For Obstructive Airway Diseases, Systemic · 1Vitamin B12 Plain · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official26 products · Rs 114.58 – Rs 5,212.86
Median across source: Rs 399.27

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Get the full profile for PARKE

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.